Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565150 | 0.90 | LNPEP (0.60) | LNPEPERAP2ERAP1ACEMMP2 | |
| SCHEMBL7857079 | 0.90 | LNPEP (0.60) | LNPEPERAP2ERAP1ACEMMP2 | |
| SCHEMBL1373290 | 0.89 | NPY4R (0.59) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| SCHEMBL15011504 | 0.89 | NPY4R (0.59) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| SCHEMBL1373292 | 0.89 | NPY4R (0.59) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| SCHEMBL30565177 | 0.89 | NPY4R (0.51) | LNPEPERAP2ERAP1NPY1RNPY2R | |
| SCHEMBL27942027 | 0.88 | NPY4R (0.62) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| Lysyl-Tyrosyl-Lysine Acetate SCHEMBL6275116 | 0.88 | NPY4R (0.62) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| Lysyl-Tyrosyl-Lysine Acetate SCHEMBL6275111 | 0.88 | NPY4R (0.62) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| SCHEMBL30851358 | 0.87 | NPY4R (0.63) | LNPEPERAP2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | claimed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | disclosed |